Cargando…
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma
This study aimed to identify associations between germline polymorphisms and risk of high-grade osteosarcoma (HGOS) development, event-free survival (EFS) and toxicity in HGOS patients treated with neo-adjuvant chemotherapy and surgery. Germline polymorphisms of 31 genes known to be relevant for tra...
Autores principales: | Hattinger, Claudia M., Biason, Paola, Iacoboni, Erika, Gagno, Sara, Fanelli, Marilù, Tavanti, Elisa, Vella, Serena, Ferrari, Stefano, Roli, Andrea, Roncato, Rossana, Giodini, Luciana, Scotlandi, Katia, Picci, Piero, Toffoli, Giuseppe, Serra, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308704/ https://www.ncbi.nlm.nih.gov/pubmed/27566557 http://dx.doi.org/10.18632/oncotarget.11486 |
Ejemplares similares
-
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells
por: Vella, Serena, et al.
Publicado: (2016) -
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013) -
Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
por: Fanelli, Marilù, et al.
Publicado: (2020) -
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
por: Hattinger, Claudia Maria, et al.
Publicado: (2023) -
Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines
por: Garofalo, Cecilia, et al.
Publicado: (2015)